Ken Griffin Atreca, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.91 - $1.82 $6,825 - $13,650
-7,500 Reduced 92.59%
600 $0
Q4 2022

Feb 14, 2023
SELL
$0.78 - $1.68 $2,574 - $5,544
-3,300 Reduced 28.95%
8,100 $6,000
Q3 2022

Nov 14, 2022
BUY
$1.59 - $2.74 $18,126 - $31,236
11,400 New
11,400 $18,000

Others Institutions Holding BCEL

# of Institutions
2
Shares Held
30.6K
Call Options Held
0
Put Options Held
0
View Full List

About Atreca, Inc.

BCEL Quotes by TradingView
  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email